DelveInsight’s “Candidemia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Candidemia pipeline landscapes. It comprises Candidemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Candidemia pipeline products.
Some of the key takeaways of the Candidemia Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such asAmplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, etc., are developing therapies for the treatment of Candidemia.
Emerging therapies such as APX001, CD101, SCY-078, are expected to have a significant impact on the Candidemia market in the coming years.
The market Size of candidemia in the 7MM was found to be USD 2,263.1 million in 2017.
Among the 7MM, the US accounted for 49.6% of the overall market size of candidemia in 2017.
Get an overview of pipeline landscape @ Candidemia Clinical Trials Analysis
Candidemia is the most common fungal bloodstream infection and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.
Candidemia Emerging Drugs
APX001 by Amplyx Pharmaceuticals
CD101 by Cidara Therapeutics
SCY-078 by Scynexis
And others.
Scope of Candidemia Pipeline Drug Insight
Coverage: Global
Major Players:Amplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, and others.
Pipeline Therapies: APX001, CD101, SCY-078, and others.
Table of Contents
1
Candidemia Report Introduction
2
Candidemia Executive Summary
3
Candidemia Overview
4
Candidemia- Analytical Perspective In-depth Commercial Assessment
5
Candidemia Pipeline Therapeutics
6
Candidemia Late Stage Products (Phase II/III)
7
Candidemia Mid Stage Products (Phase II)
8
Candidemia Early Stage Products (Phase I)
9
Candidemia Preclinical Stage Products
10
Candidemia Therapeutics Assessment
11
Candidemia Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Candidemia Key Companies
14
Candidemia Key Products
15
Candidemia Unmet Needs
16
Candidemia Market Drivers and Barriers
17
Candidemia Future Perspectives and Conclusion
18
Candidemia Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Candidemia Drugs Pipeline Report
Related Reports:
Candidemia Market
DelveInsight’s Candidemia – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Candidemia Epidemiology
DelveInsight’s ‘ Candidemia- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Candidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/